Opens in a new tab

EOFLOW v Insulet (CFI, 22 July 2025)

Date22 July 2025
CourtCFI
DivisionMilan (IT) Central Division- Section
Type of actionRevocation Action
Registry referenceACT_56003/2024 · ORD_69390/2024
PartiesEOFLOW Co., Ltd. v. Insulet Corporation

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

In a decision of 22 July 2025 (UPC_CFI_597/2024), given both on EOFLOW’s revocation action and on Insulet’s counterclaim for infringement, the Milan Central Division dismissed by default the revocation action against unitary patent EP 4 201 327, EOFLOW having refused to provide the EUR 500,000 security ordered, and then held that the EOPatch insulin pump (GlucoMen Day Pump) infringes claim 1. It granted an injunction backed by penalty payments, corrective measures, an information order and an interim award of EUR 230,000 in damages. It matters in practice for the consequence of failing to provide security and for the treatment of costs where the proprietor ran parallel proceedings against the manufacturer and the distributor.

Facts and procedure

On 3 July 2024 Insulet applied for provisional measures against EOFLOW before the Central Division and against its distributor Menarini before the Milan Local Division. EOFLOW brought its revocation action on 14 October 2024. The application for provisional measures, refused on 22 November 2024, was granted by the Court of Appeal on 30 April 2025. On 10 December 2024 Insulet filed its defence, applications to amend and its counterclaim. By order of 11 April 2025 EOFLOW was required to provide EUR 500,000 in security, the deadline later moved to 13 May 2025, at the interim conference that day EOFLOW stated that it would not pay, and Insulet requested a decision by default.

The applicable law

Rule 355 allows a decision by default where a party fails to comply with an order. Rule 355.2 requires that the facts put forward justify the remedy. Article 69(4) UPCA allows security for costs to be ordered. Corrective measures and the information order rest on Articles 64 and 67 UPCA, the interim award of damages on Rule 119, and the ceiling on recoverable costs on Rule 152.2.

Question

Does the revocation claimant’s refusal to provide the security ordered justify dismissing its action by default, and does the EOPatch pump fall within claim 1, in particular as regards the nut and the clutch of the drive mechanism?

Decision

The conditions for a decision by default were met: failure to comply with a validly issued order and a request by the other party. Dismissal served the purpose of Article 69(4), which protects a defendant against a claimant lacking the means to cover its costs, as the Court of Appeal noted on 20 June 2025 (UPC_CoA_393/2025). The sanction under Rule 355.2 is losing the case, not losing the patent. The applications to amend therefore did not need to be decided. On the counterclaim, a decision by default would have served no purpose, since the merits still had to be assessed, and the Court proceeded to a hearing. It construed the nut as a partially threaded tube nut, relying on dependent claim 2, and read “pass through” dynamically. The description and drawings act as the patent’s own lexicon without confining the claims to the preferred embodiment. All features of claim 1 were found. The Menarini settlement, filed late without leave, was disregarded. Exhaustion failed because consent was not tied to individual products. The infringement was held serious given its scale, justifying all corrective measures requested with no grace period. Penalty payments were set at EUR 30,000 per day for the injunction and EUR 15,000 for the other orders. The EUR 230,000 was fixed on an equitable basis, by reference to 69,723 units sold and a profit of at least EUR 3 per unit. The EUR 600,000 ceiling applies per instance whatever the number of parties or patents. The costs of two parallel legal teams were not recoverable and Menarini’s EUR 600,000 payment was credited, leaving EOFLOW liable for EUR 162,292 for the provisional measures proceedings, plus an interim EUR 200,000 towards the costs on the merits.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts 29, 63, 64, 67, 68, 69(4), 70 and 82(4)
Rules of Procedure
Rules 118, 119, 150, 151, 152, 157, 158, 171, 220, 221, 263, 350, 354, 355 and 356
European Patent Convention
Arts 54, 56, 69 and 138(1)
Directive 2004/48/EC
Art. 13
Case law cited
Court of Appeal, 20 June 2025, UPC_CoA_393/2025, Insulet v EOFlow, Court of Appeal, 30 April 2025, UPC_CoA_768/2024, Hanshow v VusionGroup, Court of Appeal, 29 July 2024, Meril v Edwards, Munich Local Division, 10 January 2025.

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Decisions in the same proceedings

Going further

Lexicon: Revocation action, Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.

Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.

Publications by Matthieu Dhenne: G 1/25, Take Three: Anything You Leave in the Description May Be Used Against You, The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Revocation Action
Outcome (Dhenne Avocats summary)
L’action en nullité d’EOFLOW est rejetée par défaut faute de constitution de la garantie ordonnée. La pompe EOPatch contrefait la revendication 1 du brevet EP 4 201 327, avec interdiction sous astreinte, mesures correctives, information et provision de 230 000 euros.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

  • EP 4 201 327 mentioned in: summary of the decision, Dhenne Avocats analysis Follow this patent

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 4 201 327
Fluid delivery device with transcutaneous access tool, insertion mechanism and blood glucose monitoring for use therewith
recorded proprietor: Insulet Corp
Patent at issue according to the summary or official headnote
Also mentioned in 25 other decision(s): EOFLOW v Insulet (CoA, 18 March 2026) · EOFlow v Insulet (CoA, 26 February 2026) · EOFlow v Insulet (CoA, 4 February 2026) · EOFlow v Insulet (CoA, 29 January 2026) · Herbert Smith Freehills Kramer (applicant) in Insulet v EOFLow (CoA, 2 · Insulet v EOFLOW (CFI, 15 October 2025) · EOFLOW v Insulet (CFI, ORD_26828/2025, 5 June 2025) · EOFLOW v Insulet (CFI, 28 May 2025)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: summary of the decision, Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.